PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life

PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life

Background: Effects on anticancer therapy following the integration of palliative care and oncology are rarely investigated. Thus, its potential effect is unknown. Aim: To investigate the effects of the complex intervention PALLiON versus usual care on end-of-life anticancer therapy. Design: Cluster...

Full description

Saved in:
Bibliographic Details
Published in:Palliative medicine Vol. 38; no. 2; pp. 229 - 239
Main Authors: Hjermstad, Marianne Jensen, Pirnat, Aleksandra, Aass, Nina, Andersen, Sigve, Astrup, Guro L, Dajani, Olav, Garresori, Herish, Guldhav, Kristin V, Hamre, Hanne, Haukland, Ellinor C, Jordal, Frode, Lundeby, Tonje, Løhre, Erik Torbjorn, Mjåland, Svein, Paulsen, Ørnulf, Semb, Karin A, Staff, Erik S, Wester, Torunn, Kaasa, Stein
Format: Journal Article
Language:English
Published: London, England SAGE Publications 01-02-2024
Sage Publications Ltd
Subjects:
Advanced stage
Aged
Cancer
Clinical medicine
Clinical outcomes
Clinical skills
Communication skills
Death
Death & dying
Educational programs
End of life decisions
Female
Gastrointestinal cancer
Hospitals
Humans
Integrated care
Intervention
Life expectancy
Male
Males
Neoplasms - pathology
Oncology
Original
Palliative Care
Patient-centered care
Patients
Quality of Life
Tumors
patient-reported outcomes
randomised controlled trial
Antineoplastic agents
palliative care
end-of-life care
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Effects on anticancer therapy following the integration of palliative care and oncology are rarely investigated. Thus, its potential effect is unknown. Aim: To investigate the effects of the complex intervention PALLiON versus usual care on end-of-life anticancer therapy. Design: Cluster-randomised controlled trial (RCT), registered at ClinicalTrials.gov (No. NCT01362816). The complex intervention consisted of a physician education program enhancing theoretical, clinical and communication skills, a patient-centred care pathway and patient symptom reporting prior to all consultations. Primary outcome was overall use, start and cessation of anticancer therapy in the last 3 months before death. Secondary outcomes were patient-reported outcomes. Mixed effects logistic regression models and Cox proportional hazard were used. Setting: A total of 12 Norwegian hospitals (03/2017–02/2021). Participants: Patients ⩾18 years, advanced stage solid tumour, starting last line of anticancer therapy, estimated life expectancy ⩽12 months. Results: A total of 616 (93%) patients were included (intervention: 309/control:307); 63% males, median age 69, 77% had gastrointestinal cancers. Median survival time from inclusion was 8 (IQR 3–14) and 7 months (IQR 3–12), and days between anticancer therapy start and death were 204 (90–378) and 168 (69–351) (intervention/control). Overall, 78 patients (13%) received anticancer therapy in the last month (intervention: 33 [11%]/control: 45 [15%]). No differences were found in patient-reported outcomes. Conclusion: We found no significant differences in the probability of receiving end-of-life anticancer therapy. The intervention did not have the desired effect. It was probably too general and too focussed on communication skills to exert a substantial influence on conventional clinical practice.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:0269-2163
1477-030X
1477-030X
DOI:10.1177/02692163231222391